Adjunctive use of methylphenidate in the treatment of psychotic unipolar depression.

abstract：BACKGROUND:Serotonin syndrome is a potentially fatal complication that usually occurs in the combination use of several serotonergic agents. We presented a patient with major depressive disorder under the treatment of bupropion, trazodone, and quetiapine. Serotonin syndrome developed soon after she received the first s...

journal_title：Clinical neuropharmacology

authors： Cheng YC,Liang CM,Liu HC

更新日期：2015-05-01 00:00:00

abstract：:During long-term treatment of schizophrenia with antipsychotic medication, side effects such as weight gain and tardive dyskinesia may develop, while other extrapyramidal side effects may continue. A large multicenter, double-blind, comparative trial of haloperidol decanoate and fluphenazine decanoate has been complet...

journal_title：Clinical neuropharmacology

authors： Cookson JC

更新日期：1991-01-01 00:00:00

abstract：OBJECTIVES:We investigated the effects of age on the association between early and eventual responses to paroxetine treatment in patients with major depressive disorder (MDD). METHODS:Eighty-nine patients with MDD were administered paroxetine and completed the 6-week protocol. On the basis of our previous study, we de...

journal_title：Clinical neuropharmacology

authors： Tomita T,Sato Y,Nakagami T,Tsuchimine S,Kaneda A,Kaneko S,Nakamura K,Yasui-Furukori N

更新日期：2015-01-01 00:00:00

abstract：:A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia. No risk factors for rhabdomyolysis were found, but the calcium-dependent potassium efflux, normally responsible for membrane hyperpolarization and muscle refractoriness, was severely ...

journal_title：Clinical neuropharmacology

authors： Koren W,Koren E,Nacasch N,Ehrenfeld M,Gur H

更新日期：1998-07-01 00:00:00

abstract：:A 56 year-old woman who suffered from parkinsonism, oro-lingual dyskinesia (OLD) and tardive akathisia (TA) due to sulpiride is reported. OLD and TA appeared after sulpiride withdrawal. The patient was successfully treated with tetrabenazine even a mild parkinsonism was present. TA seems to be related with an apparent...

journal_title：Clinical neuropharmacology

authors： López de Munain A,Poza JJ,Gorospe A,Arce A,Martí Massó JF

更新日期：1994-10-01 00:00:00

abstract：:Seven of 63 children (11%) treated with clobazam (CLB) for refractory epilepsy developed a severe behavior disorder. This disorder was characterized by aggressive agitation, self injurious behavior, insomnia, and incessant motor activity occurring between 10 and 55 days after initiation of drug therapy. The affected c...

journal_title：Clinical neuropharmacology

authors： Sheth RD,Goulden KJ,Ronen GM

更新日期：1994-08-01 00:00:00

abstract：:This study reports the antidepressant efficacy and the safety of amineptine (Survector 100) in a national multicenter open clinical trial (32 hospital centers). Three hundred twenty-four patients with depressive disorders, selected according to DSM-III Diagnostic Criteria and INSERM classification, were treated with a...

journal_title：Clinical neuropharmacology

authors： Kemali D

更新日期：1989-01-01 00:00:00

abstract：OBJECTIVE:Although hormone replacement therapy (HRT) improves menopausal depressive symptoms, women unresponsive to HRT need an antidepressant drug as an effective adjunctive therapy. The aim of this study was to assess whether the herbal medicine Unkei-to has an impact on HRT-resistant menopausal depressive symptoms a...

journal_title：Clinical neuropharmacology

authors： Koike K,Ohno S,Takahashi N,Suzuki N,Nozaki N,Murakami K,Sugiura K,Yamada K,Inoue M

更新日期：2004-07-01 00:00:00

abstract：:To evaluate two different dosage regimens for albendazole (7.5 mg/kg twice a day or 5.0 mg/kg three times a day), a study was performed in 10 patients with a diagnosis of parenchymal brain cysticercosis. Each patient received both regimens sequentially according to a randomized, crossover design. Blood and urine sampl...

journal_title：Clinical neuropharmacology

authors： Sánchez M,Suástegui R,González-Esquivel D,Sotelo J,Jung H

更新日期：1993-02-01 00:00:00

abstract：:This article outlines the reasons that detection of subtle changes in the cognitive system is difficult in geriatric assessment. A new assessment approach is introduced that examines cognitive patterns and facilitates the evaluation of subtle changes. ...

journal_title：Clinical neuropharmacology

authors： Poon LW

更新日期：1993-01-01 00:00:00

abstract：:Duloxetine is a serotonin-noradrenaline reuptake inhibitor that is effective in the treatment of major depressive disorder (MDD) and chronic pain. The safety of duloxetine has been shown by many previous studies. We report a patient who experienced visual hallucinations after taking duloxetine. The patient experienced...

journal_title：Clinical neuropharmacology

authors： Tomita T,Yasui-Furukori N,Kaneko S

更新日期：2013-09-01 00:00:00

abstract：:Glutamate is the predominant excitatory neurotransmitter of the basal ganglia, where it acts on ionotropic and metabotropic receptors. In the best studied of the basal ganglia disorders, Parkinson's disease, there is compelling evidence that the activities of glutamatergic pathways are altered. Of particular importanc...

journal_title：Clinical neuropharmacology

authors： Greenamyre JT

更新日期：2001-03-01 00:00:00

abstract：OBJECTIVE:To describe an unusual case of camptocormia responding to levodopa. METHODS:We present a case of camptocormia with a sustained excellent response to levodopa in a patient with negative dopamine transporter and no DYT 5 genetic mutations. RESULTS:We present a 52-year-old man with 2 years' history of progress...

journal_title：Clinical neuropharmacology

authors： Oravivattanakul S,Abboud H,Fernandez H,Itin I

更新日期：2014-03-01 00:00:00

abstract：:Drugs (e.g., PCP) which interfere with glutamatergic transmission at the N-methyl D-aspartate (NMDA) subclass of glutamate receptors precipitate both positive and negative symptoms of psychosis in humans. Based on a proposed "glutamatergic deficiency" in schizophrenia, pharmacologic facilitation of NMDA-mediated neura...

journal_title：Clinical neuropharmacology

authors： Rosse RB,Schwartz BL,Davis RE,Deutsch SI

更新日期：1991-06-01 00:00:00

abstract：:The effect and clinical significance of tolcapone withdrawal on erythrocyte catechol-O-methyltransferase (COMT) activity, levodopa pharmacokinetics, and levodopa requirements were investigated in 59 patients with fluctuating parkinsonism who were randomized to receive placebo or tolcapone 100 or 200 mg three times dai...

journal_title：Clinical neuropharmacology

authors： Jorga KM,Davis TL,Kurth MC,Saint-Hilaire MH,LeWitt PA,Fotteler B,Zürcher G,Rabbia M

更新日期：2000-03-01 00:00:00

abstract：:Myoclonic status epilepticus (MSE) in patients without epilepsy, or de novo MSE, is a rare condition associated with several acute symptomatic etiologies, including drugs and toxins. We describe a 94-year-old woman with Alzheimer dementia and long use of mirtazapine 30 mg/d and alprazolam 1 mg/d who developed MSE appr...

journal_title：Clinical neuropharmacology

authors： Vicente Ferreira Naves P,Calderaro M,Caboclo LO

更新日期：2018-07-01 00:00:00

abstract：:Recent studies have suggested that deprenyl may exert a neuroprotective influence and thus retard progression of Parkinson's disease (PD). On the other hand, the data do not disprove that deprenyl is primarily another form of symptomatic therapy like levodopa. Longitudinal Gompertzian analysis demonstrates the absence...

journal_title：Clinical neuropharmacology

authors： Riggs JE

更新日期：1991-12-01 00:00:00

abstract：:A significant proportion of the interindividual variance in human fatness is attributable to genetic factors. This fact is indicated (inter alia) by studies of identical twins demonstrating that the degree of efficiency with which the body uses excess dietary energy for fat storage is, to a considerable extent, inheri...

journal_title：Clinical neuropharmacology

authors： Van Itallie TB

更新日期：1988-01-01 00:00:00

abstract：:Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia. The current report describes a treatment-resistant patient with chronic undifferentiated schizophrenia whose most dramatic symptomatic improvements were temporarily related to the open-label addit...

journal_title：Clinical neuropharmacology

authors： Rosse RB,Kendrick K,Tsui LC,Fay-McCarthy M,Collins JP Jr,Rosenberg P,Wyatt RJ,Deutsch SI

更新日期：1995-08-01 00:00:00

abstract：:A 34-year-old man presented with severe refractory depression. He had failed to respond to various antidepressants, augmentation therapy with lithium carbonate, and modified electroconvulsive therapy. Switching from amoxapine 150 mg/day to selegiline 7.5 mg/day, a selective monoamine oxidase type-B inhibitor, produced...

journal_title：Clinical neuropharmacology

authors： Higuchi H,Kamata M,Sugawara Y,Yoshida K

更新日期：2005-07-01 00:00:00

abstract：:One hundred patients with Parkinson's disease (PD) and five patients with progressive supranuclear palsy were questioned about the frequency, circumstances, and consequences of falling. Parkinsonian symptoms were scored using the unified rating scale. Thirty-eight percent of parkinsonian patients fell, and 13% fell mo...

journal_title：Clinical neuropharmacology

authors： Koller WC,Glatt S,Vetere-Overfield B,Hassanein R

更新日期：1989-04-01 00:00:00

abstract：:Hypothermia is a potentially life-threatening emergency. This article examines the case of a 34-year-old, mentally retarded man who experienced three episodes of hypothermia during recurrent exposure to pipamperone. After the pipamperone dose was largely reduced, no further hypothermic episodes occurred. Nine other ca...

journal_title：Clinical neuropharmacology

authors： Schwaninger M,Weisbrod M,Schwab S,Schröder M,Hacke W

更新日期：1998-11-01 00:00:00

abstract：:Obsessive-compulsive disorder (OCD) is a brain disorder with recognizable periods of onset, course, familial occurrence, epidemiology, phenomenology, and treatment response. Several manifestations of pathophysiology are beginning to be defined, although they may represent intermediate pathophysiology rather than prima...

journal_title：Clinical neuropharmacology

authors： Micallef J,Blin O

更新日期：2001-07-01 00:00:00

abstract：:We report on a schizophrenic patient whose tardive dystonia, delusions, and auditory hallucinations showed remarkable concurrent improvement after replacing haloperidol with risperidone. The present finding suggests that the 5-hydroxytryptamine-2 (5-HT2) antagonistic action of risperidone has brought about the improve...

journal_title：Clinical neuropharmacology

authors： Yoshida K,Higuchi H,Hishikawa Y

更新日期：1998-01-01 00:00:00

abstract：:Fifty-six chronic schizophrenic patients were randomized into haloperidol decanoate (HD) or placebo groups for 48 weeks of double-blind treatment. The double-blind trial was preceded by a 15-week single-blind run-in period, during which all patients were treated with 60 mg of HD (approximately corresponding to 3.6 mg ...

journal_title：Clinical neuropharmacology

authors： Eklund K,Forsman A

更新日期：1991-01-01 00:00:00

abstract：OBJECTIVES:Ponezumab is a humanized antiamyloid beta (Aβ) monoclonal antibody designed to treat Alzheimer disease (AD). METHODS:This randomized, double-blind, single-dose-escalation study evaluated the safety, pharmacokinetics, and pharmacodynamics of 0.1, 0.3, 1, 3, and 10 mg/kg ponezumab (n = 4, 4, 4, 6, and 8, resp...

journal_title：Clinical neuropharmacology

authors： Landen JW,Zhao Q,Cohen S,Borrie M,Woodward M,Billing CB Jr,Bales K,Alvey C,McCush F,Yang J,Kupiec JW,Bednar MM

更新日期：2013-01-01 00:00:00

abstract：:A patient with melanoma and sporadic positive melanuria developed Parkinson's disease. Treatment with levodopa failed to modify tumoral progress. However, during chemotherapy with dacarbazine, the patient experienced a significant impairment to levodopa response. ...

journal_title：Clinical neuropharmacology

authors： Merello M,Esteguy M,Perazzo F,Leiguarda R

更新日期：1992-02-01 00:00:00

abstract：OBJECTIVE:The pathophysiology of hallucinations in Parkinson disease is poorly understood. This study investigated the relation between visual hallucination and visual evoked potentials (VEPs) in Parkinson disease. METHODS:Nineteen patients with Parkinson disease were studied. The authors divided patients into 2 group...

journal_title：Clinical neuropharmacology

authors： Matsui H,Udaka F,Tamura A,Oda M,Kubori T,Nishinaka K,Kameyama M

更新日期：2005-03-01 00:00:00

abstract：:Levodopa (LD) is one of the most effective drugs for clinical symptoms in patients with Parkinson disease (PD). Most PD patients are advanced in age and may have trouble with LD absorption because aging influences drug absorption processes. Previous reports have indicated that ascorbic acid (AsA) can reduce LD dosage ...

journal_title：Clinical neuropharmacology

authors： Nagayama H,Hamamoto M,Ueda M,Nito C,Yamaguchi H,Katayama Y

更新日期：2004-11-01 00:00:00

abstract：:In nine patients with orthostatic hypotension due to multiple system atrophy, the effects of octreotide (100 micrograms s.c.), a somatostatin analogue, on blood pressure (BP), heart rate (HR), and norepinephrine (NE) plasma levels after 60 degrees head up tilt test were evaluated by a randomly controlled study. Octreo...

journal_title：Clinical neuropharmacology

authors： Bordet R,Benhadjali J,Destée A,Belabbas A,Libersa C

更新日期：1995-02-01 00:00:00